• Home
  • Palbociclib 125mg
  • Palbociclib 125mg

Palbociclib 125mg

52067

Palbociclib is used with an aromatase inhibitor as a first hormone-based treatment for HR-positive, HER2-negative breast cancer that is advanced or has spread.

It is also used with fulvestrant when HR-positive, HER2-negative advanced or metastatic breast cancer has worsened after earlier hormone therapy.

People who have not gone through menopause usually receive ovarian-suppression treatment as well.

Usual adult dose range: 75mg to 125mg once daily on days 1 to 21 of each 28-day cycle; the usual starting dose is 125mg once daily.

Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.
  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.